For Research Purposes Only — This compound is not FDA approved.

Catalog
GLP-2 (TR) 10 MG
Metabolic Research

GLP-2 TZ (Tirzepatide)

Tirzepatide (catalogue designation GLP-2 TZ) is a dual GIP and GLP-1 receptor agonist studied for metabolic-regulation and energy-balance signaling in research models. Premium Research Peptide.

Amount
Quantity
1
Bundle & Save
COA
Only 42 left in stock 18 people viewing now
Est. delivery in 2–5 business days
Free shipment protection
Overnight shipping available

Certificate of Analysis

Third Party Tested Janoshik
99.03%
Purity · HPLC-UV
Latest BatchLC-MS IdentityThird-Party Verified
Passed QC panel
Lot TZ10-001Tested Jul 22, 2026
Purity (HPLC-UV)99.03%
Net Peptide Content10.95mg
Identity (LC-MS)GLP TZ
Janoshik · Independent third-party lab View full COA

Compound Information

Technical specifications
Molecular Profile

What is GLP-2 TZ (tirzepatide)?

CompoundTirzepatide
TypeSynthetic peptide
CAS Number2023788-19-2
Molecular Weight4,813.45 g/mol
Amino Acids39
Fatty Acid ChainC20 diacid
PubChem Database Tirzepatide Research Guide
Storage Requirements

Stability Information

Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
−20°C · 24+ months
Reconstituted
2–8°C · ~30 days

Research Background

For laboratory research use only

What tirzepatide is

Tirzepatide, listed in this catalogue as GLP-2 TZ, is a synthetic 39-amino-acid peptide with a molecular weight of 4,813.45 g/mol. It is a dual agonist: one molecule that activates both the GIP receptor and the GLP-1 receptor, the two incretin receptors. The catalogue code refers to those two targets and should not be confused with glucagon-like peptide-2, an unrelated intestinal hormone.

The sequence is built on native GIP and modified in three ways that matter to anyone working with it. Aminoisobutyric acid (Aib) residues at two positions block cleavage by DPP-4, the enzyme that inactivates natural incretins in minutes. The C-terminus is extended and amidated. And a C20 fatty diacid is attached to the lysine at position 20 through a hydrophilic linker, which makes the peptide bind serum albumin and accounts for its long residence time in pharmacokinetic studies.

What the published literature has examined

  • Imbalanced agonism. In vitro receptor studies report that tirzepatide is more potent at the GIP receptor than at the GLP-1 receptor, in contrast to a balanced co-agonist.
  • Biased signalling. At the GLP-1 receptor, published work describes a preference for cAMP generation over beta-arrestin recruitment, a property examined as a possible explanation for its pharmacology.
  • Animal models of energy balance. Rodent studies comparing the dual agonist with selective GLP-1 agonists on food intake, body composition and glucose handling.
  • Clinical literature. Tirzepatide is the active ingredient of approved prescription medicines, and there is a large clinical trial literature on those pharmaceutical products.

That last point needs stating carefully. Approved medicines are finished pharmaceutical products, manufactured under GMP, sterile, and dispensed on prescription. This research-grade material is none of those things. It is supplied for in vitro and laboratory work only, is not a medicine, and is not a substitute for one. The tirzepatide research guide covers the literature in depth, and retatrutide vs tirzepatide compares the dual agonist with the triple agonist.

How this material is characterised

The Certificate of Analysis above reports three measurements for the current lot. HPLC-UV purity is the share of the peptide signal that belongs to the main peak, as opposed to synthesis by-products such as deletion sequences or peptide missing its fatty-acid chain. LC-MS identity confirms that the main peak has the molecular mass of tirzepatide; a high purity figure says nothing about which molecule is pure. Net peptide content is the measured mass of peptide in the vial once counter-ions and residual moisture are accounted for, and is the figure to use when calculating a concentration. How to read a Certificate of Analysis and HPLC vs mass spectrometry explain each in detail.

Handling in the laboratory

Two properties of the molecule shape how it should be handled. It is lipidated, so it is surface-active: it foams when shaken and adsorbs to glass and plastic at low concentration. Reconstitute by running solvent down the vial wall and swirling, and consider low-binding tubes for dilute working solutions. It also contains a tryptophan residue, which is sensitive to light and oxidation, so the instruction to protect from light is more than a formality. Keep the lyophilised powder frozen and dry; refrigerate solutions, use them within weeks, and aliquot instead of repeatedly freezing and thawing. See peptide storage and stability and how to reconstitute a research peptide.

Common questions

Is GLP-2 TZ the same compound as tirzepatide?

Yes. GLP-2 TZ is the catalogue designation used on this site for tirzepatide, CAS number 2023788-19-2. It is not glucagon-like peptide-2, which is a different molecule. The LC-MS identity result on the Certificate of Analysis confirms the molecular mass for each lot.

Why is tirzepatide called a dual agonist?

Because a single peptide activates two receptors in in vitro assays: the GIP receptor and the GLP-1 receptor. Published receptor studies describe it as imbalanced, with greater potency at the GIP receptor.

Is this the same as the prescription medicine that contains tirzepatide?

No. Prescription medicines are finished, sterile pharmaceutical products made under GMP. This is research-grade material for in vitro and laboratory use only. It is not a medicine, not a substitute for one, and not for human or veterinary use.

Why should a tirzepatide solution not be shaken?

The C20 fatty diacid makes the peptide surface-active, so vigorous shaking produces foam and can promote aggregation. Let the solvent run down the vial wall and swirl gently until the powder dissolves.

How should lyophilised tirzepatide be stored?

Keep the lyophilised powder at -20 C, dry and protected from light. After reconstitution store at 2-8 C, avoid repeated freeze-thaw cycles and aliquot into single-use volumes where the protocol allows.

Frequently Researched Together

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

By purchasing, you confirm that you are a qualified researcher and will use these products in accordance with all applicable laws and regulations.